A Dautruche, L Belin, P Cottu, P Bontemps, C Lemanski, B de la Lande, P Baumann, F Missohou, C Lévy, K Peignaux, A Reynaud-Bougnoux, F Denis, A Gobillion, V Pernin, Y Kirova
PURPOSE: To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. MATERIAL AND METHODS: This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at 12 and 36 months after its completion...
April 9, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique